Grifols SA (GRFS)
9.665
+0.60
(+6.56%)
USD |
NASDAQ |
Nov 14, 12:41
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 6.569B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 2.02% |
Valuation | |
PE Ratio | 30.45 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 0.8868 |
Price to Book Value | 1.099 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 77.82% |
Profile
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies. |
URL | https://www.grifols.com |
Investor Relations URL | https://www.grifols.com/en/presentations-and-events |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Mid Cap/Growth |
Next Earnings Release | Feb. 28, 2025 (est.) |
Last Earnings Release | Jul. 30, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Jun. 03, 2021 |
Ratings
Profile
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies. |
URL | https://www.grifols.com |
Investor Relations URL | https://www.grifols.com/en/presentations-and-events |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Mid Cap/Growth |
Next Earnings Release | Feb. 28, 2025 (est.) |
Last Earnings Release | Jul. 30, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Jun. 03, 2021 |